Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients—May 2006
Section snippets
Background
Bisphosphonate compounds have been used for more than 15 years and have noticeably improved the lives of patients with bone metastases by reducing and delaying potentially life-threatening complications such as hypercalcemia of malignancy, pathologic fractures and spinal cord compression. This review discusses osteonecrosis of the jaw (ONJ), which is an uncommon event that has been reported in cancer patients receiving complex treatment regimens, including radiation, chemotherapy, and other
Clinical presentation and working diagnosis of ONJ
A two-stage approach is recommended to identify patients with ONJ.
- (1)
The clinical features of suspected ONJ: They are exposed bone in the maxillofacial area that occurs in association with dental surgery or occurs spontaneously, with no evidence of healing. Patients with these clinical features should be referred for appropriate dental evaluation and care as soon as possible.
- (2)
A working diagnosis of ONJ: It is made when there is no evidence of healing after 6 weeks of appropriate evaluation and
Severity and lesion size staging for ONJ
The staging criteria listed below in Table 1, Table 2 were supported by this advisory panel. This classification system was designed to be compatible with Adverse Event reporting for oncology clinical trials. The National Cancer Institute (NCI) Common Toxicity Criteria (CTC) system has a four-grade scale.
Updated recommendations for the prevention and management of ONJ in patients with cancer
The expert panel addressed a series of questions related to the prevention and management of ONJ in patients with cancer whose treatment regimens include IV bisphosphonates. In all cases, an open discussion between the treating physician and the patient is strongly recommended.
- (1)
For oncology patients, should a dental examination and preventive dentistry be performed before starting bisphosphonate therapy?
- •
It is recommended that patients be encouraged to have a dental examination before they start
- •
Conclusions and future directions
Bisphosphonate compounds have been used for more than 15 years and have noticeably improved the lives of patients with bone metastases by reducing and delaying potentially life-threatening complications such as hypercalcemia of malignancy, pathologic fractures, and spinal cord compression. Osteonecrosis of the jaw has been reported in cancer patients whose treatment regimens include IV bisphosphonates. As with all medical therapies, the potential risks and benefits of all treatments should be
Reviewers
Cesar A. Migliorati, Professor, Oral Medicine: NSU College of Dental Medicine, 3200 S. University Drive, Fort Lauderdale, FL 33328-2018, USA.
Luis A.M. Costa, Professor, Oncology Unit Hospital de Santa Maria PT-1649-035 Lisbon Portugal, Professor Jean-Jacques BODY, Department of Internal Medicine, Institute J. Bordet, Universite Libre de Bruxelles, rue Heger-Bordet 1, B-1000 Brussels, Belgium.
Robert E., Coleman, Professor, Medical Oncology, Head, Academic Unit of Clinical Oncology, Cancer
Acknowledgments
The authors wish to recognize the participants of the February, 2006 advisory board meeting who reviewed and commented on the contents of this manuscript: Dr. Douglas Joshua, Dr. Maico Melo, Dr. G. David Roodman, Dr. Jesus San Miguel, Dr. Catherine Von Poznak, and Dr. Orhan Sezer. In addition, the authors would like to extend their appreciation to Dr. Matti Aapro for his contributions and assistance with developing this manuscript.
References (50)
- et al.
Bisphosphonate-associated osteonecrosis of the jaws. Report of a case and literature review
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
(2006) - et al.
Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: a new clinical entity
Am J Med
(2004) - et al.
Bisphosphonate-associated osteonecrosis of the jaws: a review of current knowledge
J Am Dent Assoc
(2005) - et al.
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment
J Oral Maxillofac Surg
(2005) - et al.
Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: strategies for prevention and early recognition
J Am Dent Assoc
(2005) - et al.
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment
Lancet Oncol
(2006) - et al.
Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases
J Oral Maxillofac Surg
(2004) - et al.
Jaw avascular bone necrosis associated with long-term use of biphosphonates
Ann Oncol
(2005) - et al.
Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer
Ann Oncol
(2006) - et al.
Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment: two case reports
J Endod
(2005)
Avascular necrosis of the jaws: risk factors in metastatic cancer patients
J Oral Maxillofac Surg
Osteonecrosis of the jaw and oral bisphosphonate treatment
J Am Dent Assoc
Bisphosphonate-associated oral osteonecrosis
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper
J Am Dent Assoc
Bisphosphonate-associated osteonecrosis of the jaw
Mund Kiefer Gesichtschir
Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors
J Clin Oncol
Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases
J Oral Pathol Med
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors
J Clin Oncol
Jaw avascular bone necrosis associated with long-term use of bisphosphonates
Tumori
Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients
Int J Hematol
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid
Haematologica
Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates
Laryngoscope
Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment
J Clin Periodontol
Bisphosphonates (BP)-related osteonecrosis of the jaw (ONJ): clinical experience of the “Rete Oncologica di Piemonte e Valle d’Aosta” network
2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
J Clin Oncol
Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy
2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
J Clin Oncol
Cited by (164)
Photodynamic therapy and photobiomodulation therapy in zoledronic acid-induced osteonecrosis in rats
2022, Photodiagnosis and Photodynamic TherapyNasolabial Flap Improves Healing in Medication-Related Osteonecrosis of the Jaw
2018, Journal of Oral and Maxillofacial SurgerySkeletal metastasis in renal cell carcinoma: A review
2018, Annals of Medicine and SurgeryBisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw
2017, Journal of Oral and Maxillofacial SurgeryPrevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid – A prospective study over 6 years
2016, Journal of Cranio-Maxillofacial SurgerySurgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III
2016, Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology